The abstract is read at the publisher; the summary is JClub's.
In 96 adults with moderate-to-severe major depressive disorder, 15 mA left sgACC-targeted tTIS produced significantly greater HDRS-17 reductions than sham and 2 mA, at post-treatment and 1-month follow-up.
- Why it matters: Non-invasive stimulation of deep brain circuits like the sgACC is still difficult, and evidence is needed on both safety and symptom-relief efficacy for specific stimulation parameters.
- What they did: In a randomized, double-blind, sham-controlled trial, participants received 10 sessions of 2 mA, 15 mA, or sham tTIS targeting the left sgACC, with depressive symptoms tracked using HDRS-17 and exploratory PSQI and anxiety measures.
- The result: The 15 mA protocol was safe and well tolerated, showing only transient tingling, and exploratory analyses suggested improved sleep quality in both active groups, while anxiety showed no intergroup differences.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.